Blog
5-Amino-1MQ: The NNMT Inhibitor in Metabolic Research
Blog / Metabolic & GLP-1 / 5-Amino-1MQ
5-Amino-1MQ: The NNMT Inhibitor in Metabolic Research
The Blocker · Metabolic & GLP-1
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme overexpressed in white adipose tissue that disrupts NAD+ metabolism. It targets metabolic dysfunction through a completely different mechanism than GLP-1 receptor approaches.
What Is 5-Amino-1MQ?
5-Amino-1-methylquinolinium is a small molecule (not technically a peptide, ~159 Da) that selectively inhibits NNMT. It competes with nicotinamide for the enzyme’s active site, preventing the methylation and excretion of this critical NAD+ precursor.
NNMT overexpression in white adipose tissue depletes the NAD+ salvage pathway by consuming nicotinamide and converting it to excreted 1-methylnicotinamide. It also depletes S-adenosylmethionine (SAM), the universal methyl donor — disrupting methylation patterns that regulate adipocyte gene expression and energy expenditure.
How NNMT Disrupts Metabolism
The downstream consequences include reduced sirtuin activity (SIRT1-7 are NAD+-dependent), impaired mitochondrial energy production, and altered circadian regulation of metabolism.
Mechanism of 5-Amino-1MQ
5-Amino-1MQ competitively inhibits NNMT by occupying the enzyme’s catalytic pocket. This preserves nicotinamide for NAD+ salvage, restoring cellular NAD+ pools. Preclinical effects include enhanced energy expenditure, reduced white adipose tissue mass, improved insulin sensitivity, and decreased adipose inflammation.
Preclinical Evidence
The landmark Kraus et al. (2014, Nature) study showed that NNMT knockdown in adipose tissue protected mice against diet-induced obesity — reduced body weight, decreased fat mass, improved metabolic parameters — despite identical high-fat diets. Subsequent pharmacological studies with 5-Amino-1MQ have replicated these findings, showing increased VO₂, improved glucose tolerance, and reduced adipose inflammation.
Sources: Kraus D et al. PMID: 24717441; Ulanovskaya OA et al. PMID: 27984015
5-Amino-1MQ vs. GLP-1 Agonists
| Approach | 5-Amino-1MQ | GLP-1 Agonists |
|---|---|---|
| Target | NNMT enzyme (adipose) | GLP-1 receptor |
| Primary mechanism | NAD+ restoration, energy expenditure | Insulin secretion, appetite suppression |
| Appetite effect | Minimal | Strong suppression |
| Energy expenditure | Increased | Minimal |
The two approaches target different aspects of metabolic dysfunction and are not competitive alternatives — they may be complementary.
Limitations
No human clinical trials. All data is preclinical. Selectivity over other methyltransferases needs further characterization. Optimal dosing, tissue distribution, and long-term safety in humans are unknown. Chronic NNMT inhibition could theoretically affect nicotinamide clearance and methyl donor balance.
Explore 5-Amino-1MQ for Your Research
Research-grade 5-Amino-1MQ — specifications, purity, and sourcing.
Disclaimer: This article is for informational and research purposes only. 5-Amino-1MQ is sold as a research compound and is not FDA-approved for human therapeutic use.
